Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
September 22, 2025 04:32 ET | Source: Research and Markets

Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030: Advances in Next-Gen Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The revenue...
September 16, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...
September 11, 2025 09:17 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi)...
September 11, 2025 07:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further...
September 04, 2025 09:25 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026...
September 02, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
September 02, 2025 04:59 ET | Source: Research and Markets

Trends & Growth Strategies in the $13.5 Billion Cancer Gene Therapy Market 2025-2030 - Advancements CRISPR and CAR-T Solutions Propel Industry Growth

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's...
August 29, 2025 10:37 ET | Source: Research and Markets

Bicycle Toxin Conjugates Market 2025 | Clinical Trials, Therapeutic Potential, and Global Commercialization Pathways

Dublin, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The "Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms & Market Opportunity Insight 2025" report has been added to ...
August 12, 2025 08:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GRAND CAYMAN, Cayman Islands, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA...